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The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However,
a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not
known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from
two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration > 400 ng/ml),
which represents an accepted prognostic cut-off and a predictor of response to ramucirumab. Those AFP-high tumours (18% of
resected cases) were characterised by significantly lower AFP promoter methylation (p < 0.001), significant enrichment of
progenitor-cell features (CK19, EPCAM), higher incidence of BAP1 oncogene mutations (8.5% vs 1.6%) and lower mutational rates of
CTNNB1 (14% vs 30%). Specifically, AFP-high tumours displayed significant activation of VEGF signalling (p < 0.001), which might
provide the rationale for the reported benefit of ramucirumab in this subgroup of patients.
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BACKGROUND
The global disease burden of hepatocellular carcinoma (HCC) is
increasing worldwide, with an estimated 50% of cases receiving
systemic treatments for advanced stage.1,2 In the last 2 years,
several compounds have shown clinical efficacy in the first-
(lenvatinib) or second-line (regorafenib, cabozantinib) setting and
joined the standard of care, sorafenib, ultimately leading to a
median survival of 2 years with sequential therapies.1 Ramucir-
umab, a monoclonal antibody against VEGFR2, is the first drug to
demonstrate efficacy in a biomarker-driven phase III trial in HCC,
showing a survival benefit as second-line treatment in those
patients with alpha-fetoprotein (AFP) serum levels higher than
400 ng/ml.3 Nevertheless, the rationale behind the use of AFP as a
predictive biomarker is not fully understood.
AFP is a protein transcribed from the albuminoid genes located
on chromosome 4, with a known multifunctionality (i.e., binding
of hydrophobic ligands, regulation of proliferation and immuno-
modulation) provided by its multi-modular structure.4 AFP is
considered an oncofoetal protein due to its presence during foetal
development and its association with some tumour types, such as
liver, testes and ovary.4 In HCC, AFP serum concentration may vary
from normal (< 10 ng/ml) to extremely high (>100000 ng/ml).2,4
For this reason, AFP has been extensively explored as a biomarker.
For surveillance and diagnostic purposes, AFP sensitivity and
specificity depend on the established cut-off, with a global
accuracy that is suboptimal for routine clinical practice.2 As a
prognostic factor, it has been clearly demonstrated that patients
with AFP > 400 ng/ml have poor outcomes.2
Considering the prognostic and predictive capabilities of AFP in
HCC, our hypothesis is that the molecular profile of high AFP
tumours differs from those with low AFP and might be associated
with VEGF signalling. Herein, we describe the biological traits of
HCC with high serum AFP levels through a comprehensive
molecular analysis that may provide the rationale for the design
of future biomarker-driven clinical trials.
METHODS
For the purpose of the study, we analysed the molecular profiles
of 520 HCC human samples with available baseline AFP serum
concentrations, including an internal cohort of 244 surgically
resected fresh frozen samples (HEPTROMIC data set),5 and an
external publicly available cohort of 276 primary HCC from The
Cancer Genome Atlas (TCGA data set)6 (Supplementary Fig. 1).
Differential molecular patterns of HCC patients based on serum
AFP levels were obtained from whole-genome expression, DNA
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methylome profiling and whole-exome sequencing as described
in Supplementary Methods.
RESULTS
AFP serum concentrations followed a logarithmic distribution in
our internal HEPTROMIC cohort, with values ranging from 0 to
71770 ng/ml (Supplementary Fig. 2A). According to the well-
established 400 ng/ml cut-off,2 only 12% (29/244) of patients with
early HCC presented high serum levels of AFP, which was
accompanied by aberrant overexpression of the gene in the
tumour (FC= 40; p < 0.001) compared with the adjacent non-
tumoral tissue (Supplementary Fig. 2B). In accordance with
previous reports,2 high AFP serum concentration was found
significantly associated with aggressive clinical–pathological
features, poor differentiation (Supplementary Tables 1–2) and
poor overall survival (Supplementary Fig. 2C).
Based on the oncofoetal nature of AFP, we next analysed its
DNA methylation status. The AFP promoter is a low-density CpG
region that was found hypermethylated in the non-tumour-
adjacent tissues and in low AFP tumours, but hypomethylated in
AFP-high tumours (p < 0.001) (Supplementary Fig. 2D). The
inverse correlation observed between AFP promoter methyla-
tion and AFP expression (HEPTROMIC/TCGA: R=−0.56/−0.49;
p < 0.001/< 0.001) suggests that this mechanism may play a key
role in the aberrant overexpression of AFP in HCC. Indeed, TET1,
an enzyme able to reverse the DNA methylation status,7 was one
of the top genes whose expression was found significantly
associated with hypomethylation of the AFP promoter (Supple-
mentary Table 3). Whether this correlation means causation is to
be determined.
In order to determine unique somatic derangements associated
with AFP-high tumours, HCC samples were analysed by















































































































Fig. 1 AFP-high HCCs show a distinct molecular profile. a Heatmap representation of the most relevant molecular features of AFP-high
tumours (> 400 ng/ml) in comparison with AFP-low tumours in the TCGA cohort. AFP-high HCCs show higher AFP RNA expression and AFP
promoter (TSS1500) hypomethylation. In terms of somatic alterations, AFP-high tumours are associated with less CTNNB1 mutations and a
higher rate of BAP1 mutations. High AFP tumours are predicted to belong to the proliferation (Chiang) and S2 (Hoshida) classes and show a
significant enrichment of signatures of HCC with progenitor features (G1 Boyault, Hepatoblastoma Cairo, CK19 Villanueva and
EPCAM Yamashita). Finally, AFP-high tumours do not present the immune-excluded phenotype (Sia) and present overexpression of HCC
signalling pathways (IGF1R Tovar, RB1 loss-of-function Bollard, NOTCH Villanueva and mTOR Villanueva). Continuous variables (AFP RNA
expression and AFP promoter methylation) and categorical variables (the rest) were analysed by T test and Fisher’s exact test, respectively.
b Heatmap representation of the VEGF KEGG pathway activation (inferred by single sample Gene Set Enrichment Analysis) and VEGF ligands
RNA expression according to AFP serum concentration in the TCGA cohort. AFP-high tumours show higher enrichment of VEGF signalling and
overexpression of VEGFB and PGF. The mean values of each phenotype (AFP high and low) have been normalised and represented as a Z
score. c Schematic representation of the VEGF pathway in HCC according to AFP serum concentration. The overexpression of VEGFB and PGF
ligands observed in AFP-high tumours might result in an enhanced activation of VEGFR1, and at the same time, prevent VEGFA from binding
VEGFR1. The competition of VEGFA with the other ligands could favour its binding to VEGFR2, ultimately leading to its subsequent activation
and release of pro-angiogenic signals. The administration of ramucirumab (a monoclonal antibody against VEGFR2) might misbalance VEGFA
signalling towards a preferential binding of VEGFR1, where it has limited biological activity. Purple and orange lines represent VEGFB/PGF and
VEGFA signalling, respectively
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Supplementary Table 4). AFP-high tumours had fewer non-silent
CTNNB1 mutations (high= 14.1%, low= 29.9%; p= 0.009), a
feature that has been associated with T-cell priming failure8 and
resistance to immune checkpoint inhibitors.9 The lower rate of
CTNNB1 mutations is in line with the observation that AFP-high
tumours fall outside of the recently described Immune Exclusion
class of HCC.8 Mutations statistically more prevalent in the AFP-
high group included the driver gene BAP1 (high= 8.5%, low=
1.6%; p= 0.009), a member of the polycomb-group proteins,
required for long-term silencing of genes that regulate the cell
cycle and cellular differentiation.10
Aiming to explore the putative link between high AFP levels
and targetable phenotypic traits, we evaluated the enrichment of
signalling pathways and previously reported molecular classes of
HCCs1 (Fig. 1a; Supplementary Fig. 3A). High AFP tumours were
particularly associated with the proliferation and the S2 classes,
with a consistent enrichment of gene signatures defining
progenitor features and overexpression of the known epidriver
IGF211 (Supplementary Table 5) when compared with AFP-low
tumours. Moreover, the targetable signalling pathways IGF1R,
NOTCH and mTOR were upregulated in AFP-high tumours. On the
other hand, the RB1 loss-of-function signature (designed to
predict the absence of benefit to CDK4/6 inhibitors) was also a
key characteristic of AFP-high tumours. Finally, we identified VEGF
pathway enrichment in AFP-high tumours (Fig. 1b; Supplementary
Fig. 3B). While analysing the RNA expression of VEGF receptor
ligands, we observed overexpression of VEGFB and PGF, but not
VEGFA. As previously reported,12,13 VEGFB and PGF compete with
VEGFA for the binding of VEGFR1.
DISCUSSION
In this study, we confirm the aberrant tumour overexpression of
AFP in those patients with serum concentrations above 400 ng/ml
and propose DNA methylation of its promoter as the driving
mechanism of such overexpression. AFP-high tumours show a
distinct phenotype characterised by poor differentiation, enrich-
ment of progenitor features and enhanced proliferation. All these
aggressive characteristics are in line with its known prognostic
capacity and explain why the percentage of AFP > 400 ng/ml
tumours increases with disease progression (from 9% in BCLC-A to
42% in BCLC-C) (Supplementary Table 1). This is relevant since
patients at advanced stages are the ones treated with systemic
therapies. In this regard, the inclusion in this study of mostly early-
stage HCCs treated with surgical resection may partially hamper to
understand the complex biological properties of advanced
HCC. Nevertheless, we propose the VEGF ligands/receptors
interplay12,13 (unbalanced in AFP-high tumours due to VEGFB/
PGF overexpression) as a rationale for the enhanced activation of
the VEGF pathway and thus the efficacy of ramucirumab in AFP-
high HCC3 (Fig. 1c). Other signalling pathways significantly
deregulated in AFP-high tumours and worthy of further analysis
include IGF2–IGFR, mTOR, NOTCH and BAP1.
In conclusion, the aberrant overexpression of targetable
molecular signalling pathways in HCC patients with high AFP
suggests that the measurement of its serum level might serve as a
noninvasive predictive tool for biomarker-based clinical trials with
targeted therapies.
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